{
    "clinical_study": {
        "@rank": "114248", 
        "acronym": "SENPARIC", 
        "arm_group": [
            {
                "arm_group_label": "Paricalcitol", 
                "arm_group_type": "Experimental", 
                "description": "SUBGROUP 1 (G1): Oral Paricalcitol= dosis Trial Priority Index mcg/100, 3 days a week."
            }, 
            {
                "arm_group_label": "Paricalcitol, Atorvastatin", 
                "arm_group_type": "Active Comparator", 
                "description": "SUBGROUP 2 (G2): Paricalcitol (same dosis than G1) + Atorvastatin (1 daily dosis of 20 mg)"
            }, 
            {
                "arm_group_label": "Atorvastatin", 
                "arm_group_type": "Active Comparator", 
                "description": "SUBGROUP 3 (G3): Atorvastatin  (same dosis than G2)"
            }
        ], 
        "brief_summary": {
            "textblock": "Use of Paricalcitol in stage Vd Chronic Kidney Disease patients, over the effect of\n      inflammatory and oxidative stress parameters."
        }, 
        "brief_title": "Paricalcitol Over Inflammatory Parameters on Chronical Kidney Disease Patients", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Kidney Disease", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Use of Paricalcitol in stage Vd Chronic Kidney Disease patients using a permanent catheter\n      due to haemodialysis; over the effect of inflammatory and oxidative stress parameters. This\n      study uses paricalcitol (vitamin D) versus atorvastatin versus paricalcitol plus\n      atorvastatin treatments."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Vd CKD patients using haemodialysis during 3 or more months.\n\n          -  Patients attached with a permanent haemodialysis catheter since, at last 6 month\n             before the beginning of the study.\n\n          -  Stabilized Kt, over 45 litres on both sexs.\n\n          -  Using a previous atorvastatin treatment.\n\n          -  Patients without infectious processes or active inflammatory process during an 8 week\n             period before the beginning of the study.\n\n          -  2 Consecutive PTH < than 400 pg/ml; Ca<10.2 and P <7.0 mg/dl.\n\n        Exclusion Criteria:\n\n          -  Patients > 18 years.\n\n          -  Pregnant women.\n\n          -  Patients who have been hospitalized 4 weeks before the beginning of the treatment.\n\n          -  Immunosuppressor intake."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01820767", 
            "org_study_id": "SENPARIC-2011-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Paricalcitol", 
                "description": "oral Paricalcitol. 3 days per week, the same day as haemodialysis is done, during 12 weeks.", 
                "intervention_name": "Paricalcitol", 
                "intervention_type": "Drug", 
                "other_name": "Group 1"
            }, 
            {
                "arm_group_label": "Paricalcitol, Atorvastatin", 
                "description": "Oral Paricalcitol. 3 days a week, the same day as haemodialysis, during 12 weeks.\nAtorvastatin: 20 mg/day oral (1 intake) during 12 weeks.", 
                "intervention_name": "Paricalcitol, atorvastatin", 
                "intervention_type": "Drug", 
                "other_name": "G2"
            }, 
            {
                "arm_group_label": "Atorvastatin", 
                "description": "Atorvastatin: 20 mg/day oral (1 take) during 12 weeks", 
                "intervention_name": "Atorvastatin", 
                "intervention_type": "Drug", 
                "other_name": "G3"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Atorvastatin", 
                "Ergocalciferols"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Chronic Kidney Disease", 
            "Vd-stadium.", 
            "Inflammatory patterns", 
            "Paricalcitol", 
            "Atorvastatin"
        ], 
        "lastchanged_date": "March 26, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Ponferrada", 
                        "country": "Spain", 
                        "state": "(Le\u00f3n).", 
                        "zip": "24411,"
                    }, 
                    "name": "Hospital El Bierzo. Servicio de Nefrolog\u00eda."
                }, 
                "investigator": {
                    "last_name": "Ricardo Mouzo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Benjamin De Le\u00f3n, MD", 
                    "phone": "987 23 74 00"
                }, 
                "facility": {
                    "address": {
                        "city": "Le\u00f3n", 
                        "country": "Spain", 
                        "zip": "24008"
                    }, 
                    "name": "Hospital de Le\u00f3n"
                }, 
                "investigator": [
                    {
                        "last_name": "Benjam\u00edn De Le\u00f3n, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Mario Prieto, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "3", 
        "official_title": "Action of Paricalcitol Over Inflammatory Parameters on Chronical Kidney Disease (Stadium Vd)Patients Bearing Tunnelized Vascular Catheters for Haemodialysis (SENPARIC Study)", 
        "overall_contact": {
            "last_name": "Ricardo Mouzo Mirco, MD", 
            "phone": "+34 987 455 200"
        }, 
        "overall_contact_backup": {
            "last_name": "Francisco Borr\u00e1s Mandri\u00f3n, CRA", 
            "phone": "+34 91 29489410"
        }, 
        "overall_official": {
            "affiliation": "Hospital El Bierzo, Fuentesnuevas Ponferrada", 
            "last_name": "Ricardo Mouzo Mirco, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Spanish Agency of Medicines", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluation of Oxidative stress and inflammative parameters before and after the paricalcitol intake.", 
            "measure": "Concentration of oxidative enzymes and VCAM-1, ICAM-1 and TNF-\u03b1 values in blood", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01820767"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hospital El Bierzo", 
            "investigator_full_name": "Ricardo Mouzo Mirco", 
            "investigator_title": "MD", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of patients showing an improvement between the values os nutritional and anaemia parameters before and after the paricalcitol intake.", 
                "measure": "Progress of Nutritional and anaemia parameters", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Number of patients showing progress after paricalcitol intake on erythropoetin variations.", 
                "measure": "Evaluation of Erythropoetin requirement variations", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Hospital El Bierzo", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ricardo Mouzo Mirco", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2011"
    }
}